Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Andecaliximab in Crohn's Disease
NCT02405442Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Apr 2015
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 2 trial of andecaliximab in Crohn's disease, sponsored by Gilead Sciences. Started Apr 2015; status: terminated.
02
Drugs
andecaliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02405442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02405442.